Skip to content
Research Article Open access CC BY 4.0

Prevalence and Antifungal Susceptibility patterns of Candida Isolated on CHROMagarTMCandida at a Tertiary Referral Hospital, Eastern Uganda

Watsemwa Juliet Jane, Jacob Stanley Iramiot, John Bosco Kalule

Microbiology Research Journal International · pp. 1–6 · Published 28 Sep 2019

10.9734/mrji/2019/v28i630151

Abstract

Background: Pregnant women are susceptible to vaginal candidiasis and maternal vulvovaginal candidiasis is a major risk factor for colonization and/or infection of the infant. The purpose of this study was to determine the prevalence and antifungal patterns of albicans and non-albicans Candida among pregnant women attending a tertiary referral hospital. Methods: Vaginal discharge- cotton swabs were self-collected from pregnant women clinically proven to have vulvovaginal candidiasis at the antenatal clinic of a tertiary referral hospital between January and July 2018. Microscopy and culture on Sabouraud's Dextrose Agar with chloramphenicol was done on the vaginal discharge-cotton swabs. Confirmatory fungal identification was done using CHROM agarTM Candida. Antifungal susceptibility testing was carried out using the standardized Kirby Bauer method. Results: Candida were isolated from 50.81% (126/249) of the swabs  and included C. albicans (80.16%, 101/126), C. glabrata (19.05% (24/126) and C. krusei (0.79%, 1/126). Candida albicans showed resistance to amphotericin B (70.63%, 89/126), clotrimazole (11.9%, 15/126), nystatin (3.17%, 4/126), fluconazole (23.02%, 29/126), and itraconazole (17.46%, 22/126). Among the non-albican Candida species, C. glabrata showed resistance to fluconazole (100% ,24/24), amphotericin B (100% ,24/24), clotrimazole (14.29%, 18/24), nystatin (1.59%, 2/24), and itraconazole (18.25%, 23/24). C. krusei showed resistance to fluconazole (100%, 1/1), amphotericin B (100%,1/1), and itraconazole (100%, 1/1). Conclusion: The candida species commonly associated with VVC in Eastern Uganda are C. albicans C. glabrata and C. krusei. Antifungal resistance was highly prevalent among the candida isolated. The use of CHROMagarTMCandida media for identification of clinically relevant Candida should be adopted instead of conventional methods that are tedious and time consuming such that treatment is based on laboratory evidence.

Vulvovaginal candidiasis antifungal susceptibility

References (30)

  1. 1 THE JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY [DOI]
  2. 2 Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America [DOI]
  3. 3 Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species [DOI]
  4. 4 Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations [DOI]
  5. 5 Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment [DOI]
  6. 6 CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species [DOI]
  7. 7 Candida krusei , a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005 [DOI]
  8. 8 Probiotics for prevention of recurrent vulvovaginal candidiasis: a review [DOI]
  9. 9 Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern [DOI]
  10. 10 Rapid Emergence of Echinocandin Resistance in Candida glabrata Resulting in Clinical and Microbiologic Failure [DOI]
  11. 11 Boric Acid for Recurrent Vulvovaginal Candidiasis: The Clinical Evidence [DOI]
  12. 12 Regional data analysis of Candida non‐albicans strains collected in United States medical sites over a 6‐year period, 2006–2011 [DOI]
  13. 13 Use of CHROMagar Candida for the presumptive identification of Candida species directly from clinical specimens in resource-limited settings [DOI]
  14. 14 Antifungal susceptibility testing of vulvovaginal Candida species among women attending antenatal clinic in tertiary care hospitals of Peshawar [DOI]
  15. 15 Prevalence of Vaginal Candidiasis and Determination of the Occurrence of Candida Species in Pregnant Women Attending the Antenatal Clinic of Thika District Hospital, Kenya [DOI]
  16. 16 Epidemiological survey of vulvovaginal candidosis in Sfax, Tunisia [DOI]
  17. 17 Changing Trends of Vulvovaginal Candidiasis [DOI]
  18. 18 Antifungal Susceptibility Patterns of Vulvovaginal Candida species among Women Attending Antenatal Clinic at Mbarara Regional Referral Hospital, South Western Uganda [DOI]
  19. 19 Identification of Cytolytic Vaginosis Versus Vulvovaginal Candidiasis [DOI]
  20. 20 Candida tropicalis as a Predominant Isolate from Clinical Specimens and its Antifungal Susceptibility Pattern in a Tertiary Care Hospital in Southern India [DOI]
  21. 21 Vulvovaginal Candidiasis in Pregnant Women and its Importance for Candida Colonization of Newborns [DOI]
  22. 22 Speciation of Candida Species Isolated From Clinical Specimens by Using Chrom Agar and Conventional Methods
  23. 23 Antifungal susceptibility testing results of New Zealand yeast isolates, 2001–2015: Impact of recent CLSI breakpoints and epidemiological cut-off values for Candida and other yeast species [DOI]
  24. 24 Vulvovaginal candidiasis is associated with the production of germ tubes by Candida albicans [DOI]
  25. 25 Vaginal Yeast Colonization in Nonpregnant Women: A Longitudinal Study [DOI]
  26. 26 The changes of antifungal susceptibilities caused by the phenotypic switching of Candida species in 229 patients with vulvovaginal candidiasis [DOI]
  27. 27 [Vaginal candida infection in the third trimester of pregnancy].
  28. 28 [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.]
  29. 29 Antimicrobial agents and chemotherapy—1969 [DOI]
  30. 30 British Microbiology Research Journal [DOI]

Cited by 17

Lycopene, Mesoporous Silica Nanoparticles and Their Association: A Possible Alternative against Vulvovaginal Candidiasis?

Gabriela Corrêa Carvalho, Gabriel Davi Marena, Gabriela Ricci Leonardi · Molecules · 2022

Chitosan-based systems aimed at local application for vaginal infections

Victor Hugo Sousa Araujo, Maurício Palmeira Chaves de Souza, Gabriela Corrêa Carvalho · Carbohydrate Polymers · 2021

Physicochemical characterization of a lycopene‐loaded mesoporous silica nanoparticle formulation

Gabriela Corrêa Carvalho, Gabriel Davi Marena, André Luiz Carneiro Soares do Nascimento · Nano Select · 2024

Showing 6 of 17 known citations — external sources report more than can currently be individually listed.

Article metrics

Real usage data collected on this platform.

67

Page views

0

PDF downloads

52

Outbound clicks

17

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.